Efficacy and safety of the ROCK2-inhibitor belumosudil for chronic GVHD: results from a multicenter retrospective analysis of a large German-Austrian cohort of the belumosudil MAP. (PubMed, Bone Marrow Transplant) - Oct 6, 2026 - "In Europe, so far there were no standard treatment options available after failure of corticosteroids and ruxolitinib. Treatment-emergent adverse reactions CTCAE grade III-IV were mostly infectious complications and occurred in 28 patients (22%). This retrospective analysis of a large real-world cohort demonstrates efficacy and safety of belumosudil in refractory chronic GvHD patients."
Clinical • Journal • Retrospective data • Chronic Graft versus Host Disease • Graft versus Host Disease • Immunology • Transplantation
|
|
Alexander Denk; Caroline Pabst; Christina Rautenberg; Christof Scheid; Christoph Schmid; Claudia Wehr; Daniel Wolff; Darina Kodzhabasheva; Elisa Sala; Franziska Taube; Friedrich Stölzel; Giuliano Filippini Velazquez; Guido Kobbe; Helene Schmeller; Ina Rudolph; Jochen J Frietsch; Katharina Egger-Heidrich; Katharina Nickel; Katrin Strauss; Kristina Maas-Bauer; Lasse Jost; Laurenz Steiner; Mareike Verbeek; Marius Dohse; Matthias A Fante; Matthias Stelljes; Mohamad-Kamal Yaakoub; Normann Steiner; Olaf Penack; Robert Zeiser; Sara Jennrich; Silke Heidenreich; Tim Richardson; Tobias A W Holderried; Udo Holtick
|